SWBI Stock Analysis: Smith & Wesson Brands | NASDAQ
Aerospace & Defense | NASDAQ, USA | Market Cap: 612m USD | 12M Return: 57% | US8317541063 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.38M
EPS Trend: -70.0%
Qual. Beats: 2
Rev. Trend: -14.1%
Qual. Beats: 3
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Smith & Wesson Brands, Inc. (NASDAQ: SWBI) is a U.S.-based designer, manufacturer, and global seller of firearms, offering handguns (revolvers and pistols), long guns (modern sporting rifles, pistol caliber carbines, and lever-action rifles), handcuffs, suppressors, and related accessories. The company also operates a contract manufacturing segment, providing forging, heat treating, machining, finishing, plating, plastic injection molding, assembly, and distribution services to third-party businesses.
Its products are sold to firearm enthusiasts, hunters, competitive shooters, home and personal protection buyers, law enforcement, and military agencies, distributed through independent dealers, retailers, in-store merchandising, direct-to-consumer channels, and range operations, supported by print, broadcast, digital, and social media advertising. Founded in 1852 and headquartered in Maryville, Tennessee, Smith & Wesson is classified in the Consumer Discretionary sector (Leisure Products sub-industry) and competes within a tightly regulated industry where finished firearms must move through Federal Firearms License (FFL) holders, making dealer relationships and distribution logistics central to the business model.
- Modern sporting rifle shipments drive long gun segment revenue
- Federal firearm regulation proposals trigger consumer pre-buy demand cycles
- Steel input costs and tariff exposure pressure manufacturing margins
| Net Income: 24.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 15.28 > 1.0 |
| NWC/Revenue: 32.48% < 20% (prev 47.22%; Δ -14.75% < -1%) |
| CFO/TA 0.22 > 3% & CFO 113.5m > Net Income 24.5m |
| Net Debt (81.1m) to EBITDA (66.9m): 1.21 < 3 |
| Current Ratio: 3.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.5m) vs 12m ago 2.74% < -2% |
| Gross Margin: 27.44% > 18% (prev 26.54%; Δ 0.90% > 0.5%) |
| Asset Turnover: 102.3% > 50% (prev 84.99%; Δ 17.30% > 0%) |
| Interest Coverage Ratio: 5.87 > 6 (EBIT TTM 36.3m / Interest Expense TTM 6.19m) |
| A: 0.34 (Total Current Assets 247.5m - Total Current Liabilities 68.4m) / Total Assets 523.3m |
| B: 0.71 (Retained Earnings 370.5m / Total Assets 523.3m) |
| C: 0.07 (EBIT TTM 36.3m / Avg Total Assets 539.0m) |
| D: 2.50 (Book Value of Equity 373.7m / Total Liabilities 149.6m) |
| Altman-Z'' = 7.63 = AAA |
| DSRI: 0.67 (Receivables 33.0m/42.2m, Revenue 551.4m/471.4m) |
| GMI: 0.97 (GM 26.54% / 27.44%) |
| AQI: 0.88 (AQ_t 0.06 / AQ_t-1 0.07) |
| SGI: 1.17 (Revenue 551.4m / 471.4m) |
| TATA: -0.17 (NI 24.5m - CFO 113.5m) / TA 523.3m) |
| Beneish M = -3.30 (Cap -4..+1) = AA |
As of September 27, 2026, the stock is trading at USD 14.26 with a total of 419,248 shares traded. Over the past week, the price has changed by +4.55%, over one month by +6.61%, over three months by -7.40% and over the past year by +56.96%.
Current recommended Stop Loss: 13.80 (which is 3.2% or 1.1 ATR below the current price).
Smith & Wesson Brands has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy SWBI.
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 17.3 | 21% |
P/E Trailing = 24.3571
P/E Forward = 11.7786
P/S = 1.1093
P/B = 1.6006
P/EG = 0.8406
Revenue TTM = 551.4m USD
EBIT TTM = 36.3m USD
EBITDA TTM = 66.9m USD
Long Term Debt = 39.2m USD (from longTermDebt, last quarter)
Short Term Debt = 1.90m USD (from shortTermDebt, last quarter)
Debt = 106.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 33.6m
Net Debt = 81.1m USD (calculated: Debt 106.3m - CCE 25.2m)
Enterprise Value = 692.7m USD (611.6m + Debt 106.3m - CCE 25.2m)
Interest Coverage Ratio = 5.87 (Ebit TTM 36.3m / Interest Expense TTM 6.19m)
EV/FCF = 8.44x (Enterprise Value 692.7m / FCF TTM 82.0m)
FCF Yield = 11.84% (FCF TTM 82.0m / Enterprise Value 692.7m)
FCF Margin = 14.88% (FCF TTM 82.0m / Revenue TTM 551.4m)
Net Margin = 4.44% (Net Income TTM 24.5m / Revenue TTM 551.4m)
Gross Margin = 27.44% ((Revenue TTM 551.4m - Cost of Revenue TTM 400.1m) / Revenue TTM)
Gross Margin QoQ = 28.66% (prev 29.76%)
Tobins Q-Ratio = 1.32 (Enterprise Value 692.7m / Total Assets 523.3m)
Interest Expense / Debt = 5.83% (Interest Expense 6.19m / Debt 106.3m)
Taxrate = 26.24% (8.71m / 33.2m)
NOPAT = 26.8m (EBIT 36.3m * (1 - 26.24%))
Current Ratio = 3.62 (Total Current Assets 247.5m / Total Current Liabilities 68.4m)
Debt / Equity = 0.28 (Debt 106.3m / totalStockholderEquity, last quarter 373.7m)
Debt / EBITDA = 1.21 (Net Debt 81.1m / EBITDA 66.9m)
Debt / FCF = 0.99 (Net Debt 81.1m / FCF TTM 82.0m)
Total Stockholder Equity = 369.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.54% (Net Income 24.5m / Total Assets 523.3m)
RoE = 6.63% (Net Income TTM 24.5m / Total Stockholder Equity 369.2m)
RoCE = 8.90% (EBIT 36.3m / Capital Employed (Equity 369.2m + L.T.Debt 39.2m))
RoIC = 6.21% (NOPAT 26.8m / Invested Capital 431.5m)
WACC = 7.09% (E(611.6m)/V(717.9m) * Re(7.57%) + D(106.3m)/V(717.9m) * Rd(5.83%) * (1-Tc(0.26)))
Discount Rate = 7.57% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -16.91 | Cagr: -0.55%
[DCF] Terminal Value 77.97% ; FCFF base≈50.1m ; Y1≈57.4m ; Y5≈84.5m
[DCF] Fair Price = 26.55 (EV 1.27b - Net Debt 81.1m = Equity 1.19b / Shares 44.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -70.01 | EPS CAGR: -35.37% | SUE: 1.95 | # QB: 2
Revenue Correlation: -14.05 | Revenue CAGR: -0.83% | SUE: 1.14 | # QB: 3
EPS current Quarter (2026-10-31): EPS=0.08 | Chg30d=+0.00% | Revisions=+25% | Analysts=1
EPS next Quarter (2027-01-31): EPS=0.12 | Chg30d=+0.00% | Revisions=+25% | Analysts=1
EPS current Year (2027-04-30): EPS=0.55 | Chg30d=+17.02% | Revisions=+25% | GrowthEPS=+34.2% | GrowthRev=+6.8%
EPS next Year (2028-04-30): EPS=0.60 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+9.1% | GrowthRev=+2.2%